Gilead Sciences (NASDAQ:GILD) was downgraded by research analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a research note issued to investors on Wednesday, December 20th, MarketBeat.com reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $74.35. Credit Suisse Group’s price objective would suggest a potential upside of 1.19% from the company’s previous close.
GILD has been the subject of several other reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Royal Bank of Canada started coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price for the company. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Robert W. Baird restated an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Wells Fargo & Co restated a “market perform” rating and set a $81.00 target price (up from $73.00) on shares of Gilead Sciences in a report on Thursday, August 31st. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $85.03.
Gilead Sciences (NASDAQ:GILD) traded up $0.35 during trading on Wednesday, hitting $79.06. 7,870,000 shares of the stock traded hands, compared to its average volume of 8,090,000. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $103,250.00, a PE ratio of 8.99, a PEG ratio of -1.58 and a beta of 1.13. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue was down 13.2% on a year-over-year basis. During the same period last year, the firm posted $2.75 earnings per share. equities research analysts forecast that Gilead Sciences will post 8.53 earnings per share for the current year.
In related news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total value of $1,108,050.00. Following the transaction, the executive vice president now directly owns 64,613 shares in the company, valued at approximately $4,772,962.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock worth $34,072,567 in the last 90 days. 1.30% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of GILD. Welch Investments LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth $108,000. Penserra Capital Management LLC grew its position in Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences in the 3rd quarter worth $144,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences in the 2nd quarter worth $147,000. Institutional investors and hedge funds own 75.94% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences (NASDAQ:GILD) Downgraded by Credit Suisse Group to “Neutral”” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/gilead-sciences-gild-rating-lowered-to-neutral-at-credit-suisse-group.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.